Lv4
700 积分 2024-12-30 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
9天前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
16天前
已完结
GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians
16天前
已完结
Obesity in adults
17天前
已完结
Modeling energy intake and body weight effects of a long-acting amylin analogue
28天前
已完结
Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
1个月前
已完结
Complement system activation: bridging physiology, pathophysiology, and therapy
2个月前
已完结
Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals
2个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
3个月前
已完结
Amylin receptor subunit interactions are modulated by agonists and determine signaling
3个月前
已完结
皖公网安备34019202002308
